Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.46 |
| ▸ | LDHA | P00338 | 4/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3435745 | 1.00 | PTGER1 (0.46) | PTGER1LDHAOGAHRH3ACKR3 | |
| SCHEMBL3435714 | 0.92 | PTGER1 (0.46) | PTGER1LDHAOGAHRH3KDM4E | |
| SCHEMBL3435749 | 0.92 | PTGER1 (0.46) | PTGER1LDHAOGAHRH3KDM4E | |
| SCHEMBL2078959 | 0.91 | PTGER1 (0.48) | PTGER1LDHAOGAHRH3SMN1; SMN2 | |
| SCHEMBL5724256 | 0.87 | HRH3 (0.51) | OGAHRH3ACKR3SMN1; SMN2SCD | |
| SCHEMBL5723952 | 0.87 | HRH3 (0.51) | OGAHRH3ACKR3SMN1; SMN2SCD | |
| SCHEMBL3550523 | 0.85 | PTGER1 (0.46) | PTGER1LDHAOGAHRH3KDM4E | |
| SCHEMBL13161917 | 0.83 | HRH3 (0.55) | PTGER1HRH3ACKR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3435653 | 0.81 | LDHA (0.44) | PTGER1LDHAOGAKDM4EALDH1A1 | |
| SCHEMBL13634311 | 0.81 | HRH3 (0.47) | PTGER1LDHAOGAHRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | PTGER1 1115/4885LDHA 2568/4885OGA 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.